tetano
Editor, Senior Moderator
J Neuroimmunol
. 2025 Mar 19:403:578590.
doi: 10.1016/j.jneuroim.2025.578590. Online ahead of print. Ofatumumab for the treatment of COVID-19-associated autoimmune encephalitis: A case report
Zhuoran Wang[SUP] 1 [/SUP], Xiaoping Du[SUP] 2 [/SUP], Qiong Wang[SUP] 2 [/SUP], Yating Zhang[SUP] 2 [/SUP], Junhong Guo[SUP] 3 [/SUP], Huifang Wang[SUP] 4 [/SUP]
Affiliations
Autoimmune encephalitis is a rare but severe complication of Coronavirus disease 2019 (COVID-19) infection. Typically, treatment involves immunomodulatory approaches such as steroids, intravenous immunoglobulin (IVIG), or plasma exchange. While for some patients, the above treatment is not effective. Here, we report a case of COVID-19-associated encephalitis, who exhibited cognitive impairment, epileptic seizures, tachycardia, and diaphoresis, with cranial MRI findings resembling those seen in limbic encephalitis. Initially, the patient exhibited a suboptimal response to antiviral therapy, high-dose steroids, and IVIG treatment. Nevertheless, his clinical symptoms and cranial MRI abnormalities markedly improved following the administration of Ofatumumab. Administering Ofatumumab early in COVID-19-related autoimmune encephalitis may benefit patients more.
Keywords: Autoimmune encephalitis; COVID-19; IVIG; Limbic encephalitis; Ofatumumab; Steroid.
. 2025 Mar 19:403:578590.
doi: 10.1016/j.jneuroim.2025.578590. Online ahead of print. Ofatumumab for the treatment of COVID-19-associated autoimmune encephalitis: A case report
Zhuoran Wang[SUP] 1 [/SUP], Xiaoping Du[SUP] 2 [/SUP], Qiong Wang[SUP] 2 [/SUP], Yating Zhang[SUP] 2 [/SUP], Junhong Guo[SUP] 3 [/SUP], Huifang Wang[SUP] 4 [/SUP]
Affiliations
- PMID: 40154217
- DOI: 10.1016/j.jneuroim.2025.578590
Autoimmune encephalitis is a rare but severe complication of Coronavirus disease 2019 (COVID-19) infection. Typically, treatment involves immunomodulatory approaches such as steroids, intravenous immunoglobulin (IVIG), or plasma exchange. While for some patients, the above treatment is not effective. Here, we report a case of COVID-19-associated encephalitis, who exhibited cognitive impairment, epileptic seizures, tachycardia, and diaphoresis, with cranial MRI findings resembling those seen in limbic encephalitis. Initially, the patient exhibited a suboptimal response to antiviral therapy, high-dose steroids, and IVIG treatment. Nevertheless, his clinical symptoms and cranial MRI abnormalities markedly improved following the administration of Ofatumumab. Administering Ofatumumab early in COVID-19-related autoimmune encephalitis may benefit patients more.
Keywords: Autoimmune encephalitis; COVID-19; IVIG; Limbic encephalitis; Ofatumumab; Steroid.